Bacteroides fragilis is a bacterial species found in the intestinal microbiota. Its name can appear in discussions of normal gut ecology and of infection because location and strain characteristics matter. A stool count does not make those different situations equivalent.
On this page
Why strain differences matter
Some B. fragilis strains have toxin-related properties. Research has studied the effects of B. fragilis toxin on human colonic tissue, but that does not make every B. fragilis strain toxin-producing. A species-level quantity cannot be treated as a toxin test. [1]
What GI-MAP measures
GI-MAP places B. fragilis among commensal or keystone bacteria and reports targeted DNA relative to its laboratory range. This is not a culture of a normally sterile site and does not establish an invasive B. fragilis infection. A high result is a report flag, not proof that the organism has crossed the intestinal wall. [2]
Interpreting a high or low value
Start by confirming that the value belongs to B. fragilis rather than the broader Bacteroidetes phylum. Then consider symptoms, recent antibiotics, stool consistency and why testing was ordered. A low count does not demonstrate an immune deficiency; a high count does not identify an enterotoxin-producing strain.
Research about microbiome composition has not supplied a universal, clinically validated “ideal” abundance for each person. Clinical usefulness of many composition-based interpretations remains uncertain. Avoid using the flag alone to choose a probiotic, antimicrobial or restrictive diet. [3]
Common questions
Is Bacteroides fragilis always harmful?
No. Its behavior depends on strain and context. A finding in stool is different from an organism causing disease in blood or tissue.
Does a normal count rule out intestinal inflammation?
No. A bacterial quantity is not a direct inflammation assessment. See calprotectin for a different type of stool marker, with its own limitations.
Sources and review
Sources checked October 7, 2026. Manufacturer material describes the test; clinical guidance and research support the interpretation limits.
- Bacteroides fragilis toxin 2: human-colonic-tissue study, 1999
- Diagnostic Solutions Laboratory: GI-MAP interpretive guide (manufacturer specifications)
- International consensus statement on microbiome testing in clinical practice (2025)
Medical review of this article is pending. For a correction or source question, contact GI MAP Test.